RAPT Therapeutics (RAPT) RPT193 2021 EADV Congress Presentation - Slideshow

Clinical safety and efficacy of RPT193, an oral CCR4 inhibitor: Results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to- severe atopic dermatitis Robert Bissonnette1, Mark Lee2, Janet DuBois3, Joshua Rulloda4, Nadine Lee4, Daniel Johnson4, David Wustrow4, Jasmina Jankicevic4, William Ho4, Laurence Cheng4, Emma Guttman-Yassky5 EADV Late-Breaker Abstract #2746 30 September 2021 1Innovaderm Research Inc., Montreal, Quebec, Canada, 2Progressive Clinical Research, Sa ...